Lantern Pharma Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 5.44 million compared to USD 3.87 million a year ago. Basic loss per share from continuing operations was USD 0.51 compared to USD 0.36 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.82 USD | -4.75% | -6.83% | +37.15% |
05-29 | Transcript : Lantern Pharma Inc. - Special Call | |
05-24 | Lantern Pharma Files $150 Million Mixed Shelf | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.15% | 65.74M | |
+58.99% | 59.34B | |
+43.17% | 40.24B | |
-5.13% | 39.88B | |
-5.56% | 28.55B | |
+15.64% | 27.26B | |
-21.17% | 19.23B | |
+33.43% | 12.61B | |
+2.60% | 12.49B | |
+26.56% | 12.28B |
- Stock Market
- Equities
- LTRN Stock
- News Lantern Pharma Inc.
- Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024